CMD03 / Chulalongkorn University - LARVOL DELTA

Targeting diffuse intrinsic pontine glioma with IL-7Rα–enhanced B7-H3 (CMD03) chimeric antigen receptor T cell: preliminary results from phase 1 clinical trial (SITC 2025) - P1 | "Two patients developed grade 3 tumor inflammation-associated neurotoxicity (TIAN), which resolved within 24 to 72 hours following treatment with dexamethasone and anakinra. As expected with locoregional delivery, CAR T cells were not detected in peripheral blood.Conclusions Preliminary findings suggest that repeated locoregional delivery of CMD03 CAR T cells is feasible and well tolerated at the initial dose level. Continued clinical investigation is warranted to further explore the therapeutic potential of IL-7Rα-enhanced B7-H3-targeting CAR T cells in improving outcomes for children with DIPG."

CAR T-Cell Therapy • Clinical • P1 data • Brain Cancer • Diffuse Intrinsic Pontine Glioma • Glioma • Oncology • Solid Tumor • CD276 • IL7 • IL7R

Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Chulalongkorn University | Not yet recruiting ➔ Recruiting | Initiation date: Dec 2024 ➔ Apr 2025

Enrollment open • Trial initiation date • Oncology • Pediatrics • Solid Tumor • IL7R

CMD03: A Phase 1 Study of CDM03 CAR T Cell in Children With Relpase or Refractory Solid Tumors (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: Chulalongkorn University

CAR T-Cell Therapy • New P1 trial • Oncology • Pediatrics • Solid Tumor • CD276 • IFNG • IL10 • IL2 • IL6 • IL7R • TNFA

CMD03DIPG: Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Chulalongkorn University | Not yet recruiting ➔ Recruiting

CAR T-Cell Therapy • Enrollment open • Brain Cancer • CNS Tumor • Diffuse Intrinsic Pontine Glioma • Glioma • Oncology • Solid Tumor • CD276 • IL7R